Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
|
|
Eliem Therapeutics, Inc. (ELYM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additional preclinical data updates for ETX-123 expected in 2023 SEATTLE and CAMBRIDGE, UK, -- – May 11, 2023 – Eliem Therapeutics, Inc. , a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended March 31, 2023. “We were excited to share our initial preclinical ...",
"Clinical Stage Neurology Company Focused on Neuronal Excitability Disorders Corporate Presentation" |
|
| 03/06/2023 |
8-K
| Quarterly results|
Docs:
|
"Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE, UK, -- – March 6, 2023 – Eliem Therapeutics, Inc. , a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter and year ended December 31, 2022. “We are excited to advance our Kv7 program forward with ETX-123 as..." |
|
| 11/14/2022 |
8-K
| Quarterly results|
Docs:
|
"Eliem Therapeutics Reports Third Quarter Financial and Business Highlights Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in the first quarter of 2023 Cash runway expected to fund operations into 2025 SEATTLE and CAMBRIDGE, UK, -- – November 14, 2022 – Eliem Therapeutics, Inc. , a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended September 30, 2022. ...",
"2 NO FOOD EFFECT3 ETX-155" |
|
| 08/15/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 03/07/2022 |
8-K
| Quarterly results |
| 11/08/2021 |
8-K
| Investor presentation, Quarterly results |
| 09/14/2021 |
8-K/A
| Quarterly results |
| 09/13/2021 |
8-K
| Quarterly results |
|
|